Clarithromycin, a unique macrolide: A pharmacokinetic, microbiological, and clinical overview
- 31 January 1992
- journal article
- review article
- Published by Elsevier BV in Diagnostic Microbiology and Infectious Disease
- Vol. 15 (1), 39-53
- https://doi.org/10.1016/0732-8893(92)90055-x
Abstract
The in vitro and in vivo spectrum of antibacterial activity of clarithromycin is summarized and related to its human pharmacokinetics. In vitro studies by several investigators have documented clarithromycin's activity against bacterial agents of respiratory tract infections, skin and soft tissue infections, and sexually transmitted diseases. Clinical cure rates of 52%–83% (pneumonia), 79%–96% (bronchitis), 82%–96% (pharyngitis), 58% (sinusitis), and 78% (skin/skin-structure infections) have been reported in patients receiving clarithromycin in comparative trials. Respective bacteriologic eradication rates in clarithromycin recipients have been reported as 57%–89%, 79%–96%, 88%–100%, 89%, and 90%. In vitro and in vivo studies suggest that clarithromycin, when combined with its major human metabolite, 14-hydroxyclarithromycin, is also effective against Haemophilus influenzae. A New Drug Application claiming efficacy in the treatment of lower respiratory tract infection, sinusitis, pharyngitis, and skin and skin-structure infections caused by susceptible pathogens has been filed with the Food and Drug Administration (FDA). This review summarizes relevant pharmacokinetic, microbiological, and clinical data for clarithromycin.Keywords
This publication has 59 references indexed in Scilit:
- Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycinDiagnostic Microbiology and Infectious Disease, 1992
- In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination againstLegionella speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Activity of new macrolides againstBordetella pertussis andBordetella parapertussisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Comparative antimicrobial activity of the new macrolides againstBorrelia burgdorferiEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1988
- Comparative in vitro activity of the new macrolide A-56268 against anaerobic bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Comparative in vitro activity of A-56268 against respiratory tract pathogensEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Comparative in vitro activity of the new macroiide A-56268 against MycobacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria andChlamydia trachomatisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Comparative in vitro activity of A-56268 (TE-031), a new macrolide antibioticEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987